Hepatitis B immune globulin - China Biologic Products

Drug Profile

Hepatitis B immune globulin - China Biologic Products

Alternative Names: Human hepatitis B immunoglobulin

Latest Information Update: 20 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator China Biologic Products
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis B; Measles

Most Recent Events

  • 25 Feb 2016 Discontinued - Registered for Hepatitis B (Prevention) in China (IV)
  • 25 Feb 2016 Discontinued - Registered for Measles (Prevention) in China (IV)
  • 25 Feb 2016 China Biologic Products withdraws registration application from the CFDA, for hepatitis B immunoglobin intravenous injection (China Biologic Products, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top